|
The problem with these programs, which have done so much to improve the health of America's poor and elderly, is neither the size of the boomer cohort nor even their impending geezerhood. The problem is the rate of cost increase per beneficiary, according to a landmark study released two years ago by the Center on Budget and Policy Priorities (and described with admirable clarity by Ezra Klein on the American Prospect website on Feb.
23).
Respected across the political spectrum for the accuracy and relevance of its data, that liberal think tank happens to be the former professional home of Peter Orszag, the Obama administration's budget director. The center's insights into federal spending will inform policy at the highest level -- which means that reforming the way we finance and deliver medicine will be central to this government's fiscal planning. Although there are many other matters that must be addressed if we are ever to regain control of deficits when economic growth resumes -- from the abuse of tax shelters by the super-rich to the absurd rip-offs by military contractors -- the biggest money is in the health sector.
But how can we cope with rising costs when we have yet to achieve the basic national goal of providing universal coverage? Perhaps now Americans will look abroad and notice that other countries provide quality care to all of their citizens, spending less than half what we do and achieving better outcomes.
In the coming decades, countries in Europe, as well as Canada and Japan, will be able to invest their resources in energy and education, while we try to figure out how to borrow enough to keep our hospitals open. What they all have in common is that they do not devote a huge proportion of their health spending to the profits of insurance companies -- and they negotiate budgets with health providers, such as pharmaceutical companies.
The superior performance of these alternatives is at long last coming to the attention of the mainstream media, which has so long ignored it.
As always, Congress will resist change on behalf of the insurance and pharmaceutical lobbies, preferring to do nothing. But perhaps in the coming years, the public will realize that such feckless politicians should be told to go do nothing somewhere else.
© Creators Syndicate
Comments? Send a letter to the editor.Albion Monitor February
27, 2009 (http://www.albionmonitor.com)All Rights Reserved. Contact rights@monitor.net for permission to use in any format. |
|